TY - JOUR
T1 - Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine D2or D3Receptor Agonists
AU - Battiti, Francisco O.
AU - Zaidi, Saheem A.
AU - Katritch, Vsevolod
AU - Newman, Amy Hauck
AU - Bonifazi, Alessandro
N1 - Publisher Copyright:
© 2021 American Chemical Society.
PY - 2021/11/11
Y1 - 2021/11/11
N2 - Linkers are emerging as a key component in regulating the pharmacology of bitopic ligands directed toward G-protein coupled receptors (GPCRs). In this study, the role of regio- and stereochemistry in cyclic aliphatic linkers tethering well-characterized primary and secondary pharmacophores targeting dopamine D2 and D3 receptor subtypes (D2R and D3R, respectively) is described. We introduce several potent and selective D2R (rel-trans-16b; D2R Ki = 4.58 nM) and D3R (rel-cis-14a; D3R Ki = 5.72 nM) agonists while modulating subtype selectivity in a stereospecific fashion, transferring D2R selectivity toward D3R via inversion of the stereochemistry around these cyclic aliphatic linkers [e.g., (-)-(1S,2R)-43 and (+)-(1R,2S)-42]. Pharmacological observations were supported with extensive molecular docking studies. Thus, not only is it an innovative approach to modulate the pharmacology of dopaminergic ligands described, but a new class of optically active cyclic linkers are also introduced, which can be used to expand the bitopic drug design approach toward other GPCRs.
AB - Linkers are emerging as a key component in regulating the pharmacology of bitopic ligands directed toward G-protein coupled receptors (GPCRs). In this study, the role of regio- and stereochemistry in cyclic aliphatic linkers tethering well-characterized primary and secondary pharmacophores targeting dopamine D2 and D3 receptor subtypes (D2R and D3R, respectively) is described. We introduce several potent and selective D2R (rel-trans-16b; D2R Ki = 4.58 nM) and D3R (rel-cis-14a; D3R Ki = 5.72 nM) agonists while modulating subtype selectivity in a stereospecific fashion, transferring D2R selectivity toward D3R via inversion of the stereochemistry around these cyclic aliphatic linkers [e.g., (-)-(1S,2R)-43 and (+)-(1R,2S)-42]. Pharmacological observations were supported with extensive molecular docking studies. Thus, not only is it an innovative approach to modulate the pharmacology of dopaminergic ligands described, but a new class of optically active cyclic linkers are also introduced, which can be used to expand the bitopic drug design approach toward other GPCRs.
UR - http://www.scopus.com/inward/record.url?scp=85118888414&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118888414&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.1c01433
DO - 10.1021/acs.jmedchem.1c01433
M3 - Article
C2 - 34699207
AN - SCOPUS:85118888414
SN - 0022-2623
VL - 64
SP - 16088
EP - 16105
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 21
ER -